Suppr超能文献

在系统性红斑狼疮中使用 I 型干扰素诱导的 mRNA 作为药效标志物和可能的诊断标志物的研究,该研究使用了一种抗 IFNα 抗体 sifalimumab。

Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNα antibody, in systemic lupus erythematosus.

机构信息

MedImmune, Translational Sciences, One MedImmune Way, Gaithersburg, MD 20878, USA.

出版信息

Arthritis Res Ther. 2010;12 Suppl 1(Suppl 1):S6. doi: 10.1186/ar2887. Epub 2010 Apr 14.

Abstract

Type I interferons are implicated in the pathogenesis of systemic lupus erythematosus (SLE). Type I interferon-inducible mRNAs are widely and concordantly overexpressed in the periphery and involved tissues of a subset of SLE patients, and provide utility as pharmacodynamic biomarkers to aid dose selection, as well as potential indicators of patients who might respond favorably to anti-IFNα therapy in SLE. We implemented a three-tiered approach to identify a panel of type I interferon-inducible mRNAs to be used as potential pharmacodynamic biomarkers to aid dose selection in clinical trials of sifalimumab, an anti-IFNα monoclonal antibody under development for the treatment of SLE. In a single-dose escalation phase 1 trial, we observed a sifalimumab-specific and dose-dependent inhibition of the overexpression of type I interferon-inducible mRNAs in the blood of treated subjects. Inhibition of expression of type I interferon-inducible mRNAs and proteins was also observed in skin lesions of SLE subjects from the same trial. Inhibiting IFNα resulted in a profound downstream effect in these SLE subjects that included suppression of mRNAs of B-cell activating factor belonging to the TNF family and the signaling pathways of TNFα, IL-10, IL-1β, and granulocyte-macrophage colony-stimulating factor in both the periphery and skin lesions. A scoring method based on the expression of type I interferon-inducible mRNAs partitioned SLE patients into two distinct subpopulations, which suggests the possibility of using these type I interferon-inducible genes as predictive biomarkers to identify SLE patients who might respond more favorably to anti-type I interferon therapy.

摘要

I 型干扰素与系统性红斑狼疮(SLE)的发病机制有关。I 型干扰素诱导的 mRNA 在一部分 SLE 患者的外周血和受累组织中广泛且一致地过度表达,它们可作为药效动力学生物标志物,有助于选择剂量,并且可能是对 SLE 中抗 IFNα 治疗有良好反应的患者的潜在指标。我们采用了一种三级方法来鉴定一组 I 型干扰素诱导的 mRNA,作为潜在的药效动力学生物标志物,以辅助西法利单抗(一种用于治疗 SLE 的正在开发的抗 IFNα 单克隆抗体)临床试验中的剂量选择。在一项单剂量递增的 1 期临床试验中,我们观察到在接受治疗的患者的血液中,西法利单抗特异性地且呈剂量依赖性抑制 I 型干扰素诱导的 mRNA 的过度表达。在同一试验中的 SLE 患者的皮肤损伤中也观察到 I 型干扰素诱导的 mRNA 和蛋白的表达抑制。抑制 IFNα 在这些 SLE 患者中产生了深远的下游效应,包括抑制 B 细胞激活因子属于 TNF 家族和 TNFα、IL-10、IL-1β 和粒细胞-巨噬细胞集落刺激因子的信号通路的 mRNAs,在周围组织和皮肤损伤中均如此。基于 I 型干扰素诱导的 mRNA 表达的评分方法将 SLE 患者分为两个不同的亚群,这表明这些 I 型干扰素诱导的基因可能被用作预测生物标志物,以识别可能对 I 型干扰素治疗反应更好的 SLE 患者。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecb2/2991779/15dc955edaca/ar2887-1.jpg

相似文献

5
Anti-interferon alpha treatment in SLE.
Clin Immunol. 2013 Sep;148(3):303-12. doi: 10.1016/j.clim.2013.02.013. Epub 2013 Mar 1.
6
Interferon α-targeted therapy.
Nihon Rinsho Meneki Gakkai Kaishi. 2013;36(4):181-8. doi: 10.2177/jsci.36.181.

引用本文的文献

2
Type I interferon signature: a quantitative standardized method for clinical application.
Clin Exp Immunol. 2025 Jan 21;219(1). doi: 10.1093/cei/uxaf018.
5
SLE serum induces altered goblet cell differentiation and leakiness in human intestinal organoids.
EMBO Mol Med. 2024 Mar;16(3):547-574. doi: 10.1038/s44321-024-00023-3. Epub 2024 Feb 5.
6
Uncoupling interferons and the interferon signature explain clinical and transcriptional subsets in SLE.
medRxiv. 2023 Aug 28:2023.08.28.23294734. doi: 10.1101/2023.08.28.23294734.
8
Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anifrolumab.
Clin Pharmacokinet. 2023 May;62(5):655-671. doi: 10.1007/s40262-023-01238-2. Epub 2023 May 6.
9
Predicting diagnostic gene expression profiles associated with immune infiltration in patients with lupus nephritis.
Front Immunol. 2022 Dec 2;13:839197. doi: 10.3389/fimmu.2022.839197. eCollection 2022.

本文引用的文献

2
Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.
J Natl Cancer Inst. 2009 Oct 7;101(19):1308-24. doi: 10.1093/jnci/djp280. Epub 2009 Sep 8.
4
IFNalpha kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model.
Proc Natl Acad Sci U S A. 2009 Mar 31;106(13):5294-9. doi: 10.1073/pnas.0900615106. Epub 2009 Mar 11.
5
Gene-expression signatures in breast cancer.
N Engl J Med. 2009 Feb 19;360(8):790-800. doi: 10.1056/NEJMra0801289.
6
Association between IFN-alpha and primary Sjogren's syndrome.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009 Jan;107(1):e12-8. doi: 10.1016/j.tripleo.2008.09.015.
7
The genetic contribution to systemic lupus erythematosus.
Bull NYU Hosp Jt Dis. 2008;66(3):176-83.
8
The innate immune system in SLE: type I interferons and dendritic cells.
Lupus. 2008 May;17(5):394-9. doi: 10.1177/0961203308090020.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验